Latest News

Ocrelizumab approved for funding

October 7, 2019 | Advocacy, Life with MS, Treatments

Media Release – 7 October 2019 Hundreds with Multiple Sclerosis ‘Abandoned’ due to Pharmac Drug Access Criteria There’s concern that a Pharmac decision to fund the drug Ocrelizumab (Ocrevus) for certain patients with multiple sclerosis from December 1st will still […]


NEDTALKS – Important conversations about your brain

August 22, 2019 | Education, Event, Life with MS, Treatments

MS Taranaki NED TALKS on Brain Health: Time Matters Saturday 31st August, 10am to 3pm (lunch included) at Plymouth International (Quality Hotel), 220 Courtenay Street, New Plymouth. Hosted by Graham Walker, President MS Taranaki Inc with invited guests from the […]


Consultation for the funding of Ocrelizumab for RRMS

August 9, 2019 | Life with MS, Treatments

Pharmac announced on Wednesday 7th August, that they are now publicly consulting on the proposed funding of Ocrelizumab for Relapsing Remitting MS. MSNZ welcomes this announcement which we have been advocating for since May 2017. To read more about our […]


Safety Review into Alemtuzumab (Lemtrada)

April 16, 2019 | Treatments

The European Medicines Agency (EMA) announced on the 12th April it is conducting a review into the safety of MS drug alemtuzumab (Lemtrada). The EMA has launched the safety review ‘following new reports of immune-mediated conditions (caused by the body’s […]


Have your say and take our survey

June 28, 2018 | Advocacy, Support, Treatments, Uncategorised

In 2017 MSNZ officially endorsed ‘Brain Health: time matters in MS’ , an international consensus report providing recommendations on diagnosis, therapeutic strategies and improving access to treatment in MS. Since then we have used the principles to direct and provide international […]